Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale [VAS] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid for 2 weeks. After 2-week treatment, changes in clinical parameters including VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be evaluated.

Inclusion Criteria:Perinnial allergic rhinitis diagnosed by a doctorPositive for one or more of inhalant perinneal allergen in skin prick test or serum specific IgE measurementAge: 19 years or olderAllergic rhinitis symptoms not controlled (VAS ≥5) by 2-week treatment with intranasal corticosteroidExclusion Criteria:Compliance for one or more drugs in last 2 weeks: <80%Use of oral corticosteroid, oral or intranasal decongestant in last 2 weeksInitiation of allergen-specific immunotherapy in last 12 monthsSeasonal allergic rhinitisChronic rhinosinusitis other than allergic rhinitisNasal polyposisComorbid diseases including infectious, respiratory, cardiologic, renal, gastrointestinal, endocrinologic, oncologic, hemotologic and immunologic disorders which investigators judge to affect on the study significantly.Patients' rejectionPregenancy or lactation